Your browser doesn't support javascript.
loading
The Impact of Breast Cancer Treatment Delays on Survival Among South African Women.
Pumpalova, Yoanna S; Ayeni, Oluwatosin A; Chen, Wenlong Carl; Buccimazza, Ines; Cacala, Sharon; Stopforth, Laura W; Farrow, Hayley A; Mapanga, Witness; Nietz, Sarah; Phakathi, Boitumelo; Joffe, Maureen; McCormack, Valerie; Jacobson, Judith S; Crew, Katherine D; Neugut, Alfred I; Ruff, Paul; Cubasch, Herbert; O'Neil, Daniel S.
Afiliação
  • Pumpalova YS; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Ayeni OA; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Chen WC; SAMRC/Wits Developmental Pathways to Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Buccimazza I; South Africa Medical Research Council Common Epithelial Cancers Research Centre, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Cacala S; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Stopforth LW; National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
  • Farrow HA; Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Mapanga W; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Nietz S; Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Phakathi B; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Joffe M; Department of Specialized Surgery, Inkosi Albert Luthuli Central Hospital, Durban and Ngwelezane Hospital, Empangeni, University of KwaZulu-Natal, Empangeni, KwaZulu-Natal, South Africa.
  • McCormack V; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Jacobson JS; Departments of Surgery and Radiation Oncology, Grey's Hospital, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South Africa.
  • Crew KD; Departments of Surgery and Radiation Oncology, Grey's Hospital, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South Africa.
  • Neugut AI; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
  • Ruff P; Division of Medical Oncology, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Cubasch H; National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
  • O'Neil DS; Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Oncologist ; 27(3): e233-e243, 2022 03 11.
Article em En | MEDLINE | ID: mdl-35274708
ABSTRACT

BACKGROUND:

In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA).

METHODS:

We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015 and June 30, 2019, selecting women with stages I-III BC who received surgery and chemotherapy. We constructed a linear regression model estimating the impact of sociodemographic and clinical factors on TTI and separate multivariable Cox proportional hazard models by first treatment (surgery and neoadjuvant chemotherapy (NAC)) assessing the effect of TTI (in 30-day increments) on OS.

RESULTS:

Of 1260 women, 45.6% had upfront surgery, 54.4% had NAC, and 19.5% initiated treatment >90 days after BC diagnosis. Compared to the surgery group, more women in the NAC group had stage III BC (34.8% vs 81.5%). Living further away from a hospital and having hormone receptor positive (vs negative) BC was associated with longer TTI (8 additional days per 100 km, P = .003 and 8 additional days, P = .01, respectively), while Ki67 proliferation index >20 and upfront surgery (vs NAC) was associated with shorter TTI (12 and 9 days earlier; P = .0001 and.007, respectively). Treatment initiation also differed among treating hospitals (P < .0001). Additional 30-day treatment delays were associated with worse survival in the surgery group (HR 1.11 [95%CI 1.003-1.22]), but not in the NAC group.

CONCLUSIONS:

Delays in BC treatment initiation are common in SA public hospitals and are associated with worse survival among women treated with upfront surgery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos